Navigation Links
New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer

imately, cancer. This potentially devastating kinase activation carries a calling card in the form of a molecule called a phosphate.

"The phosphates signal activated tyrosine kinases," said Druker. "So we decided to use the phosphates as markers."

To find these markers, the team took myeloid leukemia cells and chemically digested them into a mixture of protein snippets called peptides. Next, they extracted all of the peptides carrying extra phosphates and sent them through a mass spectrometer, which precisely measured the weight of each peptide. Sophisticated software then sifted through a massive protein database at the National Library of Medicine, identifying each of the team's peptides as a segment of a specific protein. The analysis showed that many of the peptides came from tyrosine kinases. Scanning this list, Druker picked out five as likely suspects.

Druker's team then introduced into their leukemia cells five segments of RNA that each shut down one of the candidate kinases. Silencing four of the kinases with RNA did nothing – the cells still grew out of control. But with the fifth, the cells no longer became cancerous.

"That left one gene to sequence. We found that the gene, called JAK3, had a mutation that drives the growth of leukemia cells in mice," said Druker. Analysis of additional patient samples later identified two more mutations in the JAK3 gene.

Thomas Mercher, a postdoctoral fellow in Gilliland's lab, then tested the mutation in a mouse model. "It was important to show that the JAK3 mutation, when introduced in mice, would lead to a leukemia-like illness. It did, confirming that the JAK3 mutations play a central role in leukemia," said Gilliland.

While Druker said that only a small proportion of AML patients likely carry JAK3 mutations, he says the technique will help find other cancer-causing mutations. The process is highly technical, but it cuts the time needed to find a
'"/>




Page: 1 2 3

Related medicine news :

1. New Laser Techniques cure degeneration of the eye
2. New Technique to Study Infants Brain.
3. New Technique For Benign Breast Tumors
4. Preventing Strokes Using Less Invasive Techniques
5. New Technique To Detect Activity Of Drugs In The Body
6. New Technique To Test Stem Cells That Heal The Heart
7. A New Technique For Prediction Of Adult Height
8. Novel Technique For Targeting Small-Cell Lung Cancer
9. Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus
10. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
11. New Technique Enables Better Nursing Of Robin Sequence Infants
Post Your Comments:
(Date:5/11/2008)...iological Sciences Research Council (BBSRC) have f...tant aspects of human ageing. Working at the Univ... Cox and Dr Robert Saunders have discovered a gene...o study the effects ageing has on DNA. In new wor...esearchers demonstrate the value of this model in ...
(Date:5/11/2008)...- The situation for children,continues to worsen i...ated,from their families, many more are living in ... drinking water from ponds covered with dead bodie... is contained in a new situation report received f... most urgent needs of women,and children and clear...
(Date:5/11/2008)...nd, sometimes, surgery, , , SUNDAY, M...ly curved and flexible so that you can bend, twist...tural curve of the spine doesn,t develop properly ...his condition is known as scoliosis and it affects...nal Scoliosis Foundation. While it isn,t a dangero...
(Date:5/9/2008)...l/ -- AMDL, Inc. (Amex: ADL ),an international v...any,with operations in China through its wholly ow...nounced that its consolidated financial,statements...included in its,Annual Report on Form 10-K filed w...l 14, 2008, contained a ,going concern, qualificat...
Breaking Medicine News(10 mins):Health News:Human aging gene found in flies 2Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 2Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 3Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 4Health News:Scoliosis: An Unnatural Curve 2Health News:Scoliosis: An Unnatural Curve 3Health News:AMDL Reports Going Concern Qualification 2
...boratories (DRL) has been slapped with a lawsuit f...Inc for the generic version of the anti-depressant...ll the drug's 40 mg dosage form along with Barr La...and 20 mg dosage forms. DRL expects this to be a r...
...nificantly improves lung function, dyspnoea and qu... pulmonary disease (COPD) compared to alternative ...otropium may be the only treatment other than smok...f COPD. These latest findings are further evidence...
... new study carried out by researchers at Erasmus U...lcohol provides some protection// against dementia...n - one to three drinks a day - reduces cardiovasc...lso affects the brain, might alcohol also protect ...
...nch researchers have found that people who have be...stroke.Researcher Dr Pierre Amarenco, from// Bicha...irmed it would mark a "major advance in stroke pre...ey destabilise fatty deposits on the walls of arte...
Other Medicine News:
(Date:5/8/2008)... Conn., May 8 /- VION PHARM...the start of an investigator-sponsored,Phase I/II ...azine(R),(VNP40101M) in combination with cytarabin...ute myelogenous leukemia (AML) and high-risk,myelo...ducted under the,direction of Ellen K. Ritchie, M....
(Date:5/8/2008)...ation May Provide New Option for Clinicians Concer...ng an Oral NSAID, TAMPA, Fla., May 8 /PRNewswire-...ng global specialty pharmaceutical company, announ...ek at the American Pain Society annual,meeting dem...harmacokinetic,profile of Alpharma Pharmaceuticals...
(Date:5/7/2008)..., May 7 /- Shire plc (LSE: ...aceutical company, today,announced findings from a...reatment differences with DAYTRANA(TM) (methylphen...ged 6 to 12 years with Attention Deficit,Hyperacti...is reaffirmed,that DAYTRANA has an established saf...
(Date:5/7/2008)...eview CUSTOM III Six-Month Data to be held Tuesday...-FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today ...USTOM III trial will be presented at EuroPCR, taki...ll hold a webcast and conference call to review,th...te-breaking session. In,addition, two-year CUSTOM ...
Breaking Medicine Technology:Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week 2XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week 3XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week 4Gandek Joins QualityMetric to Lead International Research Effort 17637 1Gandek Joins QualityMetric to Lead International Research Effort 17637 2Pharma Base S A Launches Osamine 28TM 29 Pharmaceutical Grade Glucosamine in North America 17634 1NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference 4846 1NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference 4846 2NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference 4846 3Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers 4843 1Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers 4843 2Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers 4843 3
...ional Symposium on,Myelodysplastic Syndromes, TAMP...results,from a pivotal Phase II trial evaluating R... known as myelodysplastic syndromes (MDS),were pre...fitt,Cancer Center & Research Institute, at th...ing place in Florence, Italy.,Breakthrough data pr...
...re-FirstCall/ -- DURECT,Corporation announced toda...reholders with an update on its truncated Phase 3,...g for the,treatment of Alzheimer,s disease. Voyage...erved positive outcome trends among,women, but no ...ently verified the analysis performed or conclusio...
Other Medicine Technology:Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3DURECT Provides an Update to the Memryte Program Under Development,by Voyager Pharmaceutical Corp 2
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
Medicine Products: